Related Experiment Videos
Vigabatrin monotherapy in resistant neonatal seizures
P S Baxter1, D Gardner-Medwin, D D Barwick
1Department of Paediatric Neurology, Newcastle General Hospital, Newcastle-upon-Tyne, UK.
Seizure
|March 1, 1995
Summary
Vigabatrin effectively controlled seizures in infants with Ohtahara syndrome and Aicardi syndrome when conventional treatments failed. Survivors showed improved developmental outcomes, suggesting vigabatrin
Area of Science:
- Pediatric Neurology
- Epileptology
- Clinical Neuroscience
Background:
- Ohtahara syndrome and Aicardi syndrome are severe early-onset epilepsy disorders.
- Conventional anticonvulsant therapies often demonstrate limited efficacy in these conditions.
- Polymicrogyria is a potential associated neurodevelopmental abnormality.
Observation:
- Seizures in infants with Ohtahara syndrome and polymicrogyria were refractory to standard treatments.
- A preterm neonate with similar clinical features also showed resistance to conventional anticonvulsants.
- One infant diagnosed with Aicardi syndrome experienced seizure improvement.
Findings:
- Vigabatrin monotherapy successfully controlled seizures in infants with Ohtahara syndrome and polymicrogyria.
- The same vigabatrin regimen was effective for the preterm neonate with similar clinical presentations.
- Autopsy of the first infant revealed no intramyelinic edema, ruling out a specific pathological finding.
Implications:
- Vigabatrin represents a promising therapeutic option for refractory infantile spasms associated with specific syndromes.
- Improved seizure control with vigabatrin may correlate with better neurodevelopmental outcomes in survivors.
- Further research is warranted to explore vigabatrin's efficacy and safety in early-onset epilepsies.